[The clinical value of continuous perfusion percutaneous transluminal coronary angioplasty in treatment of coronary artery disease].
Fourty two patients with coronary artery disease were studied. Among them 22 were treated with continuous perfusion percutaneous transluminal coronary angioplasty (CPPTCA) and 20 with percutaneous transluminal coronary angioplasty (PTCA). It was found that patients treated with CPPTCA can stand longer time of dilatation during operation than those treated with PTCA (P < 0.01). Moreover, angina pectoris and ischemic changes of ECG occurred later during CPPTCA than during PTCA (P < 0.001). The incidences of ventricular tachycardia, ventricular fibrillation, residual trans-stenosis pressure gradient and residual stenosis were all lower in patients treated with CPPTCA than those with PTCA (P < 0.01-0.001). However, there was no significant difference in the incidence of reinfarction and one-year mortality between the patients after CPPTCA and PTCA.